Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Understanding what stocks are favored by new investors can guide your choices. Explore current buying trends to make informed decisions.
27,622 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Rumors are swirling about meta platforms reportedly getting into prediction markets. This potential pivot could redef...
Regulatory rhetoric around the Clarity Act ignites a fresh XRP debate, with Cardano founder Charles Hoskinson warning...
Shield AI just unveiled a landmark Series G round worth $1.5 billion, lifting its valuation to $12.7 billion and sett...
NIO posted a 62% year-over-year jump in May deliveries, sending stock higher as it rolls out new models. Tesla edged ...
The head of the Virtual Assets Regulatory Authority warns that the sector’s AI-driven future will advance only as fas...
Explore how Pixelworks PXLW 2026 earnings shape a small-cap tech stock. This guide breaks down the key metrics, poten...
NASA awarded the first phase of its moon base contracts to four U.S. companies, signaling a major shift in private-pu...
Regulators are pressing for clearer access and safer custody as major venues reshape how crypto trades are executed. ...
SpaceX rolls out a $60 billion bid to acquire Cursor and back new silicon ventures, aiming to tilt the AI hardware la...
S&P Global recently completed a strategic spin-off, triggering a near 8% jump in the parent stock. Here’s what happen...
Eric Trump’s American Bitcoin announced a 1-for-15 reverse stock split to protect its Nasdaq listing as its treasury ...